Nova Mentis Life Science (Nova Mentis Life Science) 3-Year FCF Growth Rate : 25.90% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science 3-Year FCF Growth Rate?

Nova Mentis Life Science's Free Cash Flow per Share for the three months ended in Mar. 2024 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 25.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 30.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Nova Mentis Life Science was 70.60% per year. The lowest was -21.10% per year. And the median was 25.90% per year.

Competitive Comparison of Nova Mentis Life Science's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Nova Mentis Life Science's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Mentis Life Science's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's 3-Year FCF Growth Rate falls into.

Nova Mentis Life Science 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Nova Mentis Life Science (OTCPK:NMLSF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Nova Mentis Life Science 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

HN3Q:Germany NOVA:Canada

Address

700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6

Website

https://www.novamentis.ca

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.